<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3170608</article-id><article-id pub-id-type="publisher-id">1745-6215-12-193</article-id><article-id pub-id-type="doi">10.1186/1745-6215-12-193</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title>The B-VITAGE trial: A randomized trial of homocysteine lowering treatment of depression in later life</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Ford</surname><given-names>Andrew H</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>forda@meddent.uwa.edu.au</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Flicker</surname><given-names>Leon</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>almeidao@meddent.uwa.edu.au</email></contrib><contrib contrib-type="author" id="A3"><name><surname>McCaul</surname><given-names>Kieran</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>almeidao@meddent.uwa.edu.au</email></contrib><contrib contrib-type="author" id="A4"><name><surname>van Bockxmeer</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="I6">6</xref><xref ref-type="aff" rid="I7">7</xref><email>almeidao@meddent.uwa.edu.au</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Hegarty</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>almeidao@meddent.uwa.edu.au</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Hirani</surname><given-names>Varsha</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>almeidao@meddent.uwa.edu.au</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Fenner</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>almeidao@meddent.uwa.edu.au</email></contrib><contrib contrib-type="author" corresp="yes" id="A8"><name><surname>Almeida</surname><given-names>Osvaldo P</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>osvaldo.almeida@uwa.edu.au</email></contrib></contrib-group><aff id="I1"><label>1</label>Western Australian Centre for Health &#x00026; Ageing, Centre for Medical Research, University of Western Australia, Perth, Australia</aff><aff id="I2"><label>2</label>School of Psychiatry &#x00026; Clinical Neurosciences, University of Western Australia, Perth, Australia</aff><aff id="I3"><label>3</label>Department of Psychiatry, Royal Perth Hospital, Perth, Australia</aff><aff id="I4"><label>4</label>School of Medicine &#x00026; Pharmacology, University of Western Australia, Perth, Australia</aff><aff id="I5"><label>5</label>Department of Geriatric Medicine, Royal Perth Hospital, Perth, Australia</aff><aff id="I6"><label>6</label>School of Pathology &#x00026; Laboratory Medicine, University of Western Australia, Perth, Australia</aff><aff id="I7"><label>7</label>Department of Biochemistry, Royal Perth Hospital, Perth, Australia</aff><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>16</day><month>8</month><year>2011</year></pub-date><volume>12</volume><fpage>193</fpage><lpage>193</lpage><history><date date-type="received"><day>13</day><month>7</month><year>2011</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2011 Ford et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Ford et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.trialsjournal.com/content/12/1/193"/><related-article related-article-type="corrected-article" id="d31e6" vol="11" page="8" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="20096138" ext-link-type="pubmed"/></article-meta></front><body><sec><title>Correction</title><p>Following the publication of our article [<xref ref-type="bibr" rid="B1">1</xref>], we noticed an error regarding the dosage of vitamin B12. In the manuscript, we reported that the daily dosage of vitamin B12 would be 0.4 mg, when in fact the dosage of vitamin B12 used in the B-VITAGE trial is 0.5 mg per day.</p><p>In the abstract:</p><p>The B-VITAGE trial is a 12-month randomized, double-blind, placebo-controlled trial of daily citalopram (20 to 40 mg) plus B<sub>12</sub>(0.4 mg), B<sub>6 </sub>(25 mg) and folic acid (2 mg) or citalopram (20 to 40 mg) plus placebo for the treatment of depression in later life.</p><p>Should read</p><p>The B-VITAGE trial is a 12-month randomized, double-blind, placebo-controlled trial of daily citalopram (20 to 40 mg) plus B<sub>12</sub>(0.5 mg), B<sub>6 </sub>(25 mg) and folic acid (2 mg) or citalopram (20 to 40 mg) plus placebo for the treatment of depression in later life.</p><p>In the "Intervention and Blinding" section:</p><p>Eligible participants will be randomly allocated to treatment with citalopram plus 400 &#x003bc;g vitamin B<sub>12</sub>, 2 mg folic acid and 25 mg B<sub>6 </sub>or citalopram plus placebo.</p><p>Should read</p><p>Eligible participants will be randomly allocated to treatment with citalopram plus 500 &#x003bc;g vitamin B<sub>12</sub>, 2 mg folic acid and 25 mg B<sub>6 </sub>or citalopram plus placebo.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Ford</surname><given-names>AH</given-names></name><name><surname>Flicker</surname><given-names>L</given-names></name><name><surname>McCaul</surname><given-names>K</given-names></name><name><surname>van Bockxmeer</surname><given-names>F</given-names></name><name><surname>Hegarty</surname><given-names>S</given-names></name><name><surname>Hirani</surname><given-names>V</given-names></name><name><surname>Fenner</surname><given-names>S</given-names></name><name><surname>Almeida</surname><given-names>OP</given-names></name><article-title>The B-VITAGE trial: A randomized trial of homocysteine lowering treatment of depression in later life</article-title><source>Trials</source><year>2010</year><volume>11</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-11-8</pub-id><pub-id pub-id-type="pmid">20096138</pub-id></mixed-citation></ref></ref-list></back></article>